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Summary.-Chemotaxis of blood monocytes was measured in 31 patients with
bronchial carcinoma and 19 cigarette smokers. Thirteen patients with metastatic
bronchial carcinoma had significantly less (P < 0.005) chemotactic response than
matched controls. Those with disease confined to the chest, or with recurrent or
operable bronchial carcinoma, had no significant depression of monocyte chemotaxis.
There was also no significant difference in monocyte chemotaxis between cigarette
smokers and matched controls. These results support the concept that in human
cancer there is a defect in monocyte chemotaxis, but in bronchial carcinoma signi-
ficant depression was only apparent in those with advanced disease.
THE role of cells of the mononuclear
phagocytic series in immune surveillance
has been suggested by a number of
workers (Hibbs, Lambert and Remington,
1972; Alexander, 1976). Forexample,anin-
hibitorofmacrophagechemotaxisproduced
by various transplanted tumours in mice
has been described (Snyderman and Pike,
1976) and in man the capacity of peri-
pheral blood monocytes to respond by
chemotaxis in vitro was depressed in
patients with genito-urinary neoplasms
(Hausman et al., 1975), malignant mela-
noma (Rubin, Cosimi and Goetzl, 1976)
and other human cancers (Boetcher and
Leonard, 1974). We have studiedmonocyte
chemotaxis from 31 patients with bron-
chial carcinoma at various clinical stages,
and also the monocyte chemotactic
response of cigarette smokers who are
known to be at risk for developing
bronchial neoplasms.
PATIENTS AND CONTROLS
Patients w%ith bronchial carcinoma were
classified according to the stage of their
disease. Those with small tumours deemed
suitable for surgical resection were termed
operable. Disease which reappeared locally at
the site of a surgical resection was termed
recurrentt. Disease confined to the chest had
spread locally from the primary site in the
bronchus to involve surrounding lung, local
lymph nodes and chest wall. The metastatic
group had deposits of tumour outside the
chest, commonly in liver or bone, as demon-
strated clinically, or by radionuclide scan-
ning.
Controls for the cancer groups were all
convalescent, hospitalized patients who had
sustained either myocardial infarctions or
respiratory infections and in whom there was
no evidence of malignant disease. Controls for
cigarette smokers were all healthy, non-
smoking volunteers.
MATERIALS AND METHODS
Human peripheral-blood monocytes were
separated on a Ficoll-Triosil gradient as
previously described (Boyum, 1968). Chemo-
taxis was quantified either by the "leading
front" method using Millipore filters (Milli-
pore Co., Wembley) of 8 jum pore size
(Zigmond and Hirsch, 1973) or bythe method
of Snyderman et al., (1972) employing
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Nucleopore filters and polycarbonate Boyden
chambers" Neuroprobe, Bethesda, Maryland,
U.S.A.). The only modification was that the
suspending medium for monocytes and for
dilutions ofchemoattractant was Medium 199
containing 30 mM Hepes buffer. The chemo-
attractant was either human serum in w%Nhich
the complement system had been activated
with purified cobra venom factor (CVF)
(Ballow and Cochrane, 1969) or solutions of
casein (British Drug Houses). Casein was
used in the early part of the study, but its
chemoattracting properties often deteriorated
after a few days, even under a variety of
storage conditions. The experiments with
casein reported here are with freshly prepared
material. In contrast, serum activated with
CVF was divided into portions after pre-
paration and stored at - 80°C until use.
The chemotactic responses from patients
with bronchial carcinoma or cigarette smokers
were compared with age- and sex-matched
controls and each pair was performed on the
same day under the same experimental
conditions. A three-point dose-response of
chemoattractant was performed for each
experiment. Optimal monocyte migration of
cells, either from patients or smokers, was
achieved with 0 5 mg/ml of fresh casein or
2.5% CVF-activated serum. Each assay was
performed in duplicate, and measurements
from each filter were the pooled results from
10 random high-power fields. The test and
control samples were analysed by the
Wilcoxon test of paired differences. The
variation between duplicate filters was ±15%
as previously described (Turnbull and Kay,
1976; Turnbull, Evans and Kay, 1977).
RESULTS
Bronchial carcinomia
The clinical staging and histology of the
31 patients with bronchial carcinoma are
shown in Table I. Apart from one indi-
vidual, all patients were male, and were
matched with controls within 10 years of
their age. The monocyte chemotactic
response of patients with metastatic
disease, and their respective controls, are
shown in Table I, together with the
histology and the treatment being received
either at the time of sampling or before
the chemotactic assay. There was a
significantly greater depression in the
TABLE I.-Clinical Staging and Predomi-
nant Histology of the 31 Patients Studied
with Bronchial Carcinoma
Clinical stage
Metastatic
Confinedl to chest
Recurrent
Operable
Histology
Anaplastic
Squamous
Oat cell
Adenocarcinoma
tTnknown
13
12
2
4
6
10
5
1
9
monocyte chemotactic response in the
metastatic group (P < 0.005) than in
their respective controls. No statistical
difference was observed with patients with
disease confined to the chest, recurrent
cancer or operable disease (Table III, Fig.).
It is unlikely that the observed effect with
the metastatic group was a result of
medication. Three ofthe 13 were receiving
antibiotics and one had treatment with
prednisolone, but most of the patients
were receiving no treatment at the time
of the chemotactic test. The two patients
receiving prednisolone in the group with
disease confined to the chest had higher
chemotactic responses than the control,
whereas the one in the metastatic
group having corticosteroids had a lower
chemotactic response.
In the Fig. the results are expressed as
the percent migration of each patient's
monocytes as compared to their respective
matched contol. With the patients as a
whole there was a wide scatter; however,
the metastatic group responded signifi-
cantly less in monocyte chemotaxis. The
one patient who gave a high response had
a pulmonary infection with a white-cell
count of 17,000/,l. There was no signi-
ficant difference between patients and
controls in the other groups, although with
operable and recurrent cancer the numbers
were very small.
Cigarette smokers
The monocyte chemotactic response of
19 male cigarette smokers, compared with
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S 0
0
S I
* 0 * 0
Total Metastatic Confined
to Chest
Operable Recurrent
Significance N.S. P 0.005 N.S. N.S. N.S.
SMOKERS
* > 20g/day
O < 20g/day
0
Q
0
5,)
N.S.
FIG. The monocyte chemotactic response of patients with various clinical stages of bronchial
carcinoma, and cigarette smokers, expressed as the percent migration of each patient's monocytes
compared to its matchedl control. NS = not significant.
TABLE II.-The Histology, Treatment and Monocyte Chemotactic Response ofPatients with
Metastatic Bronchial Carcinoma. Controls were Matchedfor Age and Sex
Prior treatment
(interval between end
of treatment
and chemotaxis test
PR (22 months)
PR (3 years)
PR (1 day)
Monocyte chemotaxis
(distance migrated
in ,um)
Medication at r-- '
time of test Pt. Control
19-7 26-8
35 9 17-2
Prednisolone 7 6 13 - 3
Ampicillin 2 0 16 - 0
8-0 17-0
2-0 18-0
Ampicillin 0 5 17 -0
8-3 23-7
26-4 33-5
13-4 33-5
53-6 59.0
Ampicillin 15-0 17 - 6
46 -4 49 7
PR = palliative radiotherapy. The chemoattractant was complement-activated serum (255%) in Patients
1 to 10 and casein (0.5 mg/ml) in Patients I to 13.
non-smoking controls, is shown in Table
IV and the Fig. There was no significant
difference between the two groups as a
whole, nor when the smokers were divided
into those who smoked more or less than
20 g per day.
DISCUSSION
Our results support previous findings on
depressed monocyte chemotactic responses
in various human cancers (Hausman et al.,
1975; Rubin et al., 1976; Boetcher and
Leonard, 1974). In the present study on
bronchial carcinoma, only those patients
with metastatic disease showed a signifi-
cant depression (Table II, Fig.). Although
this may have been a non-specific effect
due to general debilitation it was unlikely
to be the result of treatment. Many of the
patients were receiving no medication at
the time of sampling and had not received
prior chemotherapy or radiotherapy
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Pt. No.
1
2
3
4
5
6
7
8
9
10
11
12
13
Age
(Years)
Pt. Control
67 69
62 61
55 59
66 61
54 60
85 75
73 73
78 71
56 55
61 55
53 53
69 65
65 65
Histology
Unknown
Anaplastic
Oat cell
Unknown
Unknown
Unknown
Unknown
Unknown
Oat cell
Oat cell
Anaplastic
Squamous
Squamous
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TABLE III.-TheHistology, Treatment andMonocyte ChemotacticResponseofPatientswith
Bronchial Carcinoma that was Confined to the Chest, Recurrent or Operable. Controls
were Matchedfor Age and Sex
Age
(years)
Pt.
No. Pt. Control Histology
1 61 69 Anaplastic
65
66
63
62
65
51
55
58
80
65
57
Squamous
Anaplastic
Squamous
Anaplastic
Unknown
Oat cell
Adenocarcinoma
Oat cell
Squamous
Unknown
Squamous
13 82 81 Unknown
14 53 55 Squamous
61
48
54
65
Squamous
Squamous
Anaplastic
Squamous
Prior treatment
(interval since end of
treatment until chemotaxis
test)
Confined to bhest
PR (20 weeks)
PR (24 weeks)
PR (23 days)
Chemotherapy (16 weeks)
Chemotherapy (6 weeks)
Recurrent
Operable
Post-surgery (3 weeks)
Monocyte chemotaxis
(distance
migrated injum)
Medication at,
time of test Pt. Control
Ampicillin, 24 0
Prednisolone
Oxytetracycline 13 -9
Ampicillin 14-0
-- 16-1
17-1
Prednisolone 20- 7
21-1
- 25-9
- 33 0
37 -8
36-4
58 -6
Oxytetracycline 42 -5
20 0
12-7
18-4
50 2
17-2
48-1
12-9
15*2
33 -5
23-6
59-8
46-9
50-2
30-6
18 -4
18-8 17-2
8-0 11.0
Ampicillin 28 0 31-0
Ampicillin 28 -8 12 -3
PR = palliative radiotherapy. The chemoattractant was casein (0.5 mg/ml) in Patients and controls 9 to 12
and 18. In the others it was complement-activated serum (2.5%).
TABLE IV.-The Monocyte Chemotactic Response of 19 Male
Cigarette Smokers Compared with Non-smoking Male Controls
Age
(years)
e C Smoker Control
Tobacco
smoked/day
(g)
60
60
53
40
36
30
30
26
23
21
20
20
20
20
20
16
15
29
14
Monocyte chemotaxis
No. of years (mean cell count)
smoking A
Smoker Control
41 49 76
45 45 53
31 65 61
17 76 53
19 66 74
38 116 90
35 17 38
40 *46 31
47 57 48
8 82 81
16 43 70
35 76 95
14 37 28
8 84 76
23 84 66
10 134 72
36 65 100
5 75 91
28 50 59
The chemoattractant was 2-5% CVF-activated serum, with the exception of the pair indicated (*) in which
the concentration was 1-25%.
2
3
4
5
6
7
89
9
10
11
12
68
62
61
60
64
51
54
67
80
68
57
15
16
17
18
65
50
57
68
56
62
49
42
40
52
49
58
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27
35
48
32
25
47
28
54
29
53
63
51
42
33
55
64
31
44
60
22
34
54
28
27
34
23
55
29
49
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(Tables II and III). In a similar study on
malignant melanoma (Rubin et al., 1976),
only patients with advanced disease had a
monocyte defect.
The inhibitor ofmacrophage chemotaxis
produced by various transplanted neo-
plasms in the peritoneal cavity of mice
was partially identified as a protein of
mol. wt. 6000-10,000 (Snyderman and
Pike, 1976). A similar inhibitor is possibly
elaborated from human neoplasms and if
it is related to tumour mass this may
account for the effect observed in the
metastatic group in the present study.
A recent leading article in the Lancet
(1976), discussing the possible role of
macrophages in tumour surveillance,
emphasized the present difficulties in
relating in vitro data from man and
experimental animals to the clinical situa-
tion. Nevertheless, if tumour-derived
material with inhibitory effects on mono-
cyte function can be demonstrated, this
may provide some additional evidence to
support the concept that tumour products
overcome possible tumoricidal effects of
mononuclear phagocytes. Experiments
currently in progress suggest that extracts
of human tumours may inhibit the
chemotactic response of normal blood
monocytes (Abell, C. and Kay, A. B.,
unpublished).
Cigarette smokers showed no difference
from controls in their monocyte migratory
capacity, indicating that monocyte chemo-
taxis will not be useful in detecting
individuals at risk for developing bronchial
carcinoma (Table IV). Studies with human
alveolar macrophages obtained from
smoking and non-smoking volunteers
demonstrated both an increase in the
number of cells recovered by bronchial
lavage and of the chemotactic response of
these cells from smokers when compared to
controls (Warr and Martin, 1974). This
suggests that cigarette smoke probably
has an initial non-specific "macrophage-
activating effect" analogous to the influx
of macrophages into tissues treated with
various irritants such as mineral oil and
glycogen.
The chemotactic activity of human
serum activated with cobra venom factor
is due almost entirely to the fragment
cleaved from the 5th component of
complement (C5a) liberated as a result of
activation ofthe alternate pathway. When
CVF-activated serum is placed on either
side of the micropore chamber, migration
is either minimal or absent, suggesting
that this agent evokes chemotaxis, (i.e.
directional migration) rather than random
migration (Kay, unpublished).
There are difficulties in employing the
chemotactic assay for clinical studies.
The reasons include possible deterioration
of the chemoattractant during storage,
variations in an individual's cell response
with time, and failure to reproduce this
biological assay exactly on each occasion.
In the present study these difficulties were
largely overcome by matching each patient
or smoker with a control individual for
age and sex, withdrawing blood from each
pair at the same time and performing the
test under identical conditions. Compari-
sonofthese matchedpairsbytheWilcoxon
test of paired differences allowed stati-
stical analysis.
Thus the present study suggests that
defects in monocyte chemotaxis are only
apparent at advanced stages of bronchial
carcinoma, and not in those with rela-
tively confined disease or in those indi-
viduals who are at risk for developing
bronchial neoplasms.
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